What the superinvestors bought and sold in 2025 Q2
2025 Q2
136 of 137 filedThe quarter at a glance
65 of 136 managers were net sellers. Setting price aside, they took $13.4B out, led by Communication Services (−$8.1B), while adding to Health Care (+$7.8B). AMZN was the most widely bought stock (24 bought, 13 sold); V the most widely sold (16 sold, 5 bought).
Net buyers
64 of 136 managers
65 sold more than they bought · 7 about even
Net bought
−$13.4B
Price moves taken out; prices alone moved the book +$105.9B.
Positions opened
764
636 closed out. IPOs, spin-offs and mergers left out.
Combined book, last quarter
+11.6%
SPY +10.5%,
1.1 pts ahead.
Price only.
Most bought and sold
Ranked by how many managers bought minus how many sold, with price moves taken out. Open a stock to see who.
Most bought
-
1 AMZN Amazon.com, Inc. 24 bought · 13 sold +$2.9B
Bought by
- Altarock Partners added 19.9% → 25.1%
- Valueact Capital - Valueact Holdings added 2.3% → 15.2%
- Chris James - Meritage Group added 8.9% → 13.6%
- Eric Mandelblatt - Soroban Capital Partners added 4.8% → 10.3%
- David Tepper - Appaloosa added 5.7% → 9.2%
- Ram Parameswaran - Octahedron Capital Management added 5.5% → 8.2%
- Stephen Mandel - Lone Pine Capital added 7.2% → 7.9%
- Dan Loeb - Third Point added 6.8% → 7.8%
and 16 more
Sold by
- Grant Wonders - Voyager Global Management cut 14.1% → 12.0%
- Polen Capital Management cut 10.6% → 9.4%
- Nehal Chopra - Ratan Capital Management cut 10.2% → 5.6%
- Ben Jacobs - Anomaly Capital Management cut 9.8% → 5.0%
- John Armitage - Egerton Capital (UK) cut 9.3% → 7.5%
- Philippe Laffont - Coatue Management cut 9.0% → 6.2%
- Alex Sacerdote - Whale Rock Capital Management cut 8.3% → 4.8%
- Christopher Davis - Davis Selected Advisers cut 3.9% → 3.8%
and 5 more
-
2 NVDA Nvidia Corporation 20 bought · 10 sold +$2.3B
Bought by
- Brad Gerstner - Altimeter Capital Management added 15.6% → 18.8%
- Grant Wonders - Voyager Global Management opened 12.2% of book
- Glen Kacher - Light Street Capital Management added 9.7% → 11.4%
- Marc Stad - Dragoneer Investment Group opened 10.3% of book
- Alex Sacerdote - Whale Rock Capital Management added 3.5% → 7.9%
- Lee Ainslie - Maverick Capital added 5.4% → 7.0%
- Dan Loeb - Third Point added 2.4% → 5.8%
- Chase Coleman - Tiger Global Management added 4.5% → 5.4%
and 12 more
Sold by
- Nehal Chopra - Ratan Capital Management cut 10.3% → 6.7%
- Ram Parameswaran - Octahedron Capital Management cut 6.7% → 5.7%
- Gavin Baker - Atreides Management cut 3.6% → 3.0%
- Estuary Capital Management closed was 2.5%
- Andreas Halvorsen - Viking Global Investors cut 2.3% → 1.7%
- Davidson Kempner Capital Management cut 1.6% → 1.3%
- Murphy Pohlad - Murphy Pohlad Asset Management cut 0.27% → 0.32%
- David Katz - Matrix Asset Advisors cut 0.13% → 0.13%
and 2 more
-
3 UNH Unitedhealth Group, Inc. 21 bought · 12 sold +$4.1B
Bought by
- David Tepper - Appaloosa added 1.1% → 11.9%
- Estuary Capital Management added 12.1% → 7.0%
- Vulcan Value Partners added 1.5% → 7.0%
- Stephen Mandel - Lone Pine Capital opened 3.8% of book
- Mairs & Power added 4.9% → 3.3%
- Samantha Mclemore - Patient Capital Management opened 2.7% of book
- Lewis Sanders - Sanders Capital added 4.1% → 2.5%
- Torray Investment Partners added 1.7% → 2.2%
and 13 more
Sold by
- Ruane, Cunniff & Goldfarb cut 7.8% → 4.1%
- Mala Gaonkar - Surgocap Partners closed was 7.0%
- David Witzke - Avidity Partners Management cut 5.0% → 2.0%
- Muhlenkamp & Co. closed was 4.3%
- Andreas Halvorsen - Viking Global Investors closed was 3.6%
- Jensen Investment Management cut 3.5% → 0.04%
- Polen Capital Management cut 1.7% → <0.01%
- David Katz - Matrix Asset Advisors closed was 1.0%
and 4 more
-
4 TEVA Teva Pharmaceutical Inds Ltd 9 bought · 0 sold +$201M
Bought by
- Glenview Capital Management added 5.6% → 7.4%
- Stanley Druckenmiller - Duquesne Family Office added 7.5% → 6.6%
- Harry Burn - Sound Shore Management added 2.9% → 3.3%
- David Einhorn - DME Capital Management added 0.44% → 2.7%
- David Witzke - Avidity Partners Management added 1.4% → 2.3%
- Lee Ainslie - Maverick Capital added <0.01% → 1.1%
- Andreas Halvorsen - Viking Global Investors added 0.49% → 0.57%
- Cathie Wood - Ark Investment Management added 0.01% → 0.01%
and 1 more
Sold by
No manager sold.
-
5 TMO Thermo Fisher Scientific Inc. 13 bought · 4 sold +$197M
Bought by
- Lindsell Train added 7.0% → 8.2%
- Wallace Weitz - Weitz Investment Management added 3.3% → 3.3%
- Farallon Capital Management added 2.9% → 2.4%
- David Witzke - Avidity Partners Management added 1.5% → 2.4%
- Arnold Van Den Berg - Van Den Berg Management I added 1.3% → 1.6%
- Glenview Capital Management opened 1.1% of book
- David Katz - Matrix Asset Advisors added 0.86% → 0.88%
- Robert Olstein - Olstein Capital Management opened 0.61% of book
and 5 more
Sold by
- Polen Capital Management cut 3.6% → 2.7%
- Ako Capital cut 2.1% → 0.14%
- Ron Baron - Bamco Inc. (Baron Capital) cut 0.06% → 0.03%
- Torray Investment Partners closed was 0.03%
-
6 IBKR Interactive Brokers Group In 6 bought · 0 sold +$1.2B
Bought by
- Bryan Lawrence - Oakcliff Capital Partners added 22.5% → 28.5%
- Robert Vinall - Rv Capital AG added 7.8% → 8.7%
- John Armitage - Egerton Capital (UK) added 3.5% → 4.6%
- William Von Mueffling - Cantillon Capital Management added 3.5% → 4.1%
- George Soros - Soros Fund Management added 0.49% → 1.6%
- Ron Baron - Bamco Inc. (Baron Capital) added 0.44% → 0.63%
Sold by
No manager sold.
-
7 SE Sea Ltd 9 bought · 3 sold +$352M
Bought by
- Glen Kacher - Light Street Capital Management opened 3.9% of book
- Alex Sacerdote - Whale Rock Capital Management opened 3.1% of book
- Ben Jacobs - Anomaly Capital Management opened 2.7% of book
- Gavin Baker - Atreides Management opened 1.5% of book
- Stanley Druckenmiller - Duquesne Family Office opened 1.2% of book
- Sarah Ketterer - Causeway Capital Management added 0.54% → 0.54%
- Howard Marks - Oaktree Capital Management opened 0.23% of book
- Dan Loeb - Third Point opened 0.10% of book
and 1 more
Sold by
- Andreas Halvorsen - Viking Global Investors cut 1.7% → 1.6%
- Christopher Davis - Davis Selected Advisers cut 0.39% → 0.38%
- Cathie Wood - Ark Investment Management cut 0.22% → 0.18%
-
8 BLDR Builders Firstsource Inc. 7 bought · 1 sold +$167M
Bought by
- Alex Roepers - Atlantic Investment Management opened 7.1% of book
- Glenn Greenberg - Brave Warrior Advisors added 3.6% → 4.9%
- Gavin Baker - Atreides Management opened 1.0% of book
- Francois Rochon - Giverny Capital added 0.38% → 0.35%
- John Armitage - Egerton Capital (UK) opened 0.31% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.24% of book
- Ron Baron - Bamco Inc. (Baron Capital) opened 0.02% of book
Sold by
- Ruane, Cunniff & Goldfarb closed was 0.01%
-
9 W Wayfair Inc. 6 bought · 0 sold +$62M
Bought by
- Ben Tsai - Spruce House Investment Management added 3.6% → 5.7%
- Gavin Baker - Atreides Management added 0.63% → 1.0%
- Glenview Capital Management added 0.27% → 0.76%
- Davidson Kempner Capital Management added 0.26% → 0.42%
- Lee Ainslie - Maverick Capital added 0.04% → 0.06%
- Polen Capital Management opened <0.01% of book
Sold by
No manager sold.
-
10 AMAT Applied Matls Inc. 8 bought · 3 sold +$1.4B
Bought by
- Harry Burn - Sound Shore Management opened 2.3% of book
- Lewis Sanders - Sanders Capital opened 1.9% of book
- David Katz - Matrix Asset Advisors opened 0.95% of book
- Ben Hoskin - Value Aligned Research Advisors added 0.60% → 0.43%
- George Soros - Soros Fund Management added 0.11% → 0.19%
- Thomas Gayner - Markel Group opened 0.03% of book
- Mairs & Power added 0.01% → 0.02%
- Bill Nygren / Oakmark - Harris Associates L P opened <0.01% of book
Sold by
- Torray Investment Partners cut 1.1% → 0.84%
- Rule One Partners closed was 0.85%
- Dan Sundheim - D1 Capital Partners closed was 0.46%
Not counted as buying: 187 IPOs, spin-offs and new listings.
Most sold
-
1 V Visa Inc. 5 bought · 16 sold +$430M
Sold by
- Valueact Capital - Valueact Holdings cut 10.0% → 7.9%
- Ako Capital cut 8.1% → 7.4%
- Eric Mandelblatt - Soroban Capital Partners cut 7.4% → 4.8%
- Polen Capital Management cut 6.6% → 6.1%
- Terry Smith - Fundsmith cut 6.6% → 5.9%
- David Rolfe - Wedgewood Partners cut 6.4% → 5.7%
- Wallace Weitz - Weitz Investment Management cut 6.0% → 5.7%
- Altarock Partners cut 6.0% → 3.5%
and 8 more
Bought by
- Chris Hohn - Tci Fund Management added 13.4% → 13.4%
- Grant Wonders - Voyager Global Management added 4.7% → 8.1%
- John Armitage - Egerton Capital (UK) added 3.9% → 7.0%
- David Katz - Matrix Asset Advisors added 0.04% → 0.04%
- Murray Stahl - Horizon Kinetics Asset Management added 0.02% → 0.02%
-
2 CVNA Carvana Co. 2 bought · 11 sold −$2B
Sold by
- Josh Kushner - Thrive Capital Management cut 80.5% → 32.4%
- Clifford Sosin - Cas Investment Partners cut 77.2% → 80.8%
- Robert Vinall - Rv Capital AG cut 25.3% → 31.8%
- Ram Parameswaran - Octahedron Capital Management cut 7.1% → 2.9%
- Senator Investment Group cut 4.6% → 2.1%
- Stephen Mandel - Lone Pine Capital cut 4.2% → 4.2%
- Alex Sacerdote - Whale Rock Capital Management cut 4.2% → 2.7%
- Henry Ellenbogen - Durable Capital Partners cut 3.6% → 2.3%
and 3 more
Bought by
- Philippe Laffont - Coatue Management added 0.49% → 1.7%
- Polen Capital Management opened 0.01% of book
-
3 PM Philip Morris Intl Inc. 2 bought · 11 sold −$861M
Sold by
- Thomas Russo - Gardner Russo & Quinn cut 8.9% → 9.4%
- Terry Smith - Fundsmith cut 7.8% → 7.2%
- Stanley Druckenmiller - Duquesne Family Office cut 5.7% → 3.7%
- Stephen Mandel - Lone Pine Capital cut 4.1% → 3.6%
- Dan Sundheim - D1 Capital Partners cut 3.7% → 3.1%
- First Eagle Investment Management cut 3.0% → 2.6%
- Philippe Laffont - Coatue Management cut 1.1% → 0.66%
- John Rogers - Ariel Investments closed was 0.20%
and 3 more
Bought by
- Andreas Halvorsen - Viking Global Investors added 1.6% → 1.8%
- Bill Nygren / Oakmark - Harris Associates L P added <0.01% → <0.01%
-
4 BABA Alibaba Group Holding, Ltd. 0 bought · 9 sold −$826M
Sold by
- David Tepper - Appaloosa cut 14.6% → 12.4%
- Duan Yongping - H&H International Investment cut 4.4% → 3.7%
- Sarah Ketterer - Causeway Capital Management cut 3.7% → 2.2%
- Samantha Mclemore - Patient Capital Management cut 3.6% → 2.6%
- Philippe Laffont - Coatue Management cut 2.2% → 0.27%
- Brad Gerstner - Altimeter Capital Management closed was 1.4%
- Ron Baron - Bamco Inc. (Baron Capital) cut 0.59% → 0.29%
- Tweedy, Browne Co. cut 0.05% → 0.04%
and 1 more
Bought by
No manager bought.
-
5 MSFT Microsoft Corp. 17 bought · 25 sold −$2.6B
Sold by
- Gates Foundation Trust cut 25.6% → 27.3%
- Eric Mandelblatt - Soroban Capital Partners cut 21.8% → 19.0%
- Grant Wonders - Voyager Global Management cut 15.2% → 8.0%
- Chris James - Meritage Group cut 14.3% → 15.3%
- Vulcan Value Partners cut 9.8% → 11.0%
- Terry Smith - Fundsmith cut 9.2% → 10.7%
- Lewis Sanders - Sanders Capital cut 7.4% → 8.5%
- Jensen Investment Management cut 7.4% → 9.1%
and 17 more
Bought by
- Chris Hohn - Tci Fund Management added 15.0% → 17.2%
- Chase Coleman - Tiger Global Management added 8.8% → 9.6%
- John Armitage - Egerton Capital (UK) added 5.8% → 9.4%
- Brad Gerstner - Altimeter Capital Management added 7.4% → 7.6%
- Ben Jacobs - Anomaly Capital Management opened 7.4% of book
- Lee Ainslie - Maverick Capital added 2.8% → 5.6%
- Philippe Laffont - Coatue Management added 5.4% → 5.4%
- Senator Investment Group added 3.5% → 4.0%
and 9 more
-
6 WFC Wells Fargo & Co. 1 bought · 9 sold −$679M
Sold by
- Tweedy, Browne Co. cut 4.1% → 4.4%
- Harry Burn - Sound Shore Management cut 3.1% → 2.9%
- First Pacific Advisors cut 3.0% → 2.3%
- Dodge & Cox cut 2.4% → 2.3%
- Senator Investment Group closed was 1.9%
- Murphy Pohlad - Murphy Pohlad Asset Management cut 0.53% → 0.47%
- Thomas Russo - Gardner Russo & Quinn cut 0.05% → 0.02%
- Lewis Sanders - Sanders Capital closed was 0.02%
and 1 more
Bought by
- Richard Pzena - Pzena Investment Management added 2.5% → 2.7%
-
7 GOOGL / GOOG Alphabet 18 bought · 25 sold −$3.3B
Sold by
- Bill Ackman - Pershing Square closed was 14.0%
- Eric Mandelblatt - Soroban Capital Partners cut 12.1% → 8.3%
- Altarock Partners cut 10.7% → 3.4%
- Tweedy, Browne Co. cut 9.4% → 5.5%
- David Rolfe - Wedgewood Partners cut 8.3% → 7.6%
- Chris Hohn - Tci Fund Management cut 6.4% → 5.6%
- Vulcan Value Partners cut 5.5% → 5.6%
- Jensen Investment Management cut 4.7% → 4.9%
and 17 more
Bought by
- Andrew Steginsky - Steginsky Capital added 22.5% → 24.9%
- Grant Wonders - Voyager Global Management added 20.0% → 19.1%
- Ram Parameswaran - Octahedron Capital Management added 10.1% → 13.5%
- Seth Klarman - Baupost Group added 9.3% → 11.3%
- Pat Dorsey - Dorsey Asset Management added 10.6% → 10.5%
- Lindsell Train added 0.08% → 8.4%
- Lewis Sanders - Sanders Capital added 7.8% → 8.4%
- Gavin Baker - Atreides Management added 0.89% → 4.6%
and 10 more
-
8 BRK.B / BRK.A Berkshire Hathaway 3 bought · 10 sold +$2.7B
Sold by
- Thomas Russo - Gardner Russo & Quinn cut 21.9% → 18.5%
- Tweedy, Browne Co. cut 16.1% → 14.9%
- Christopher Davis - Davis Selected Advisers cut 9.3% → 5.6%
- Torray Investment Partners cut 3.3% → 2.6%
- Don Yacktman - Yacktman Asset Management cut 2.8% → 2.3%
- Harry Burn - Sound Shore Management cut 2.7% → 1.9%
- First Eagle Investment Management cut 1.5% → 0.95%
- Robert Olstein - Olstein Capital Management cut 0.86% → 0.69%
and 2 more
Bought by
- Christopher Bloomstran - Semper Augustus Investments Group added 35.5% → 28.8%
- Gates Foundation Trust added 21.9% → 24.5%
- Andrew Steginsky - Steginsky Capital added 7.4% → 6.8%
-
9 SCHW The Charles Schwab Corp. 1 bought · 7 sold −$1.2B
Sold by
- Ruane, Cunniff & Goldfarb cut 9.6% → 10.3%
- Dan Sundheim - D1 Capital Partners cut 5.2% → 4.5%
- Andreas Halvorsen - Viking Global Investors cut 4.4% → 4.2%
- Bill Nygren / Oakmark - Harris Associates L P cut 3.6% → 3.4%
- Lee Ainslie - Maverick Capital closed was 2.0%
- John Rogers - Ariel Investments cut 0.51% → 0.42%
- Mairs & Power cut 0.41% → 0.30%
Bought by
- Francois Rochon - Giverny Capital added 2.7% → 4.9%
-
10 EXPE Expedia Group, Inc. 0 bought · 6 sold −$212M
Sold by
- Lyrical Asset Management cut 4.4% → 3.9%
- Valueact Capital - Valueact Holdings cut 4.1% → 0.84%
- Glenview Capital Management cut 2.7% → 2.4%
- Samantha Mclemore - Patient Capital Management cut 2.4% → 2.0%
- Ron Baron - Bamco Inc. (Baron Capital) closed was 0.05%
- Lee Ainslie - Maverick Capital cut 0.05% → <0.01%
Bought by
No manager bought.
Not counted as selling: 161 mergers and delistings.
Opened and closed
New positions started from zero, and positions sold down to zero. IPOs, spin-offs and mergers are left out.
Opened by the most managers
-
SE Sea Ltd 8 managers avg 1.6% of book · Glen Kacher - Light Street Capital Management, Alex Sacerdote - Whale Rock Capital Management and 6 more
Opened by
- Glen Kacher - Light Street Capital Management opened 3.9% of book
- Alex Sacerdote - Whale Rock Capital Management opened 3.1% of book
- Ben Jacobs - Anomaly Capital Management opened 2.7% of book
- Gavin Baker - Atreides Management opened 1.5% of book
- Stanley Druckenmiller - Duquesne Family Office opened 1.2% of book
- Howard Marks - Oaktree Capital Management opened 0.23% of book
- Dan Loeb - Third Point opened 0.10% of book
- Polen Capital Management opened 0.04% of book
-
NVDA Nvidia Corporation 6 managers avg 4.3% of book · Grant Wonders - Voyager Global Management, Marc Stad - Dragoneer Investment Group and 4 more
Opened by
- Grant Wonders - Voyager Global Management opened 12.2% of book
- Marc Stad - Dragoneer Investment Group opened 10.3% of book
- Jensen Investment Management opened 3.2% of book
- Christopher Davis - Davis Selected Advisers opened 0.08% of book
- Torray Investment Partners opened 0.05% of book
- Polen Capital Management opened <0.01% of book
-
META Meta Platforms Inc. 6 managers avg 1.6% of book · Eric Mandelblatt - Soroban Capital Partners, Ben Jacobs - Anomaly Capital Management and 4 more
Opened by
- Eric Mandelblatt - Soroban Capital Partners opened 4.1% of book
- Ben Jacobs - Anomaly Capital Management opened 2.5% of book
- Jensen Investment Management opened 1.8% of book
- Dan Loeb - Third Point opened 1.5% of book
- Steven Check - Check Capital Management opened <0.01% of book
- Glenn Greenberg - Brave Warrior Advisors opened <0.01% of book
-
GOOGL / GOOG Alphabet 6 managers avg 1.5% of book · Ben Jacobs - Anomaly Capital Management, Harry Burn - Sound Shore Management and 4 more
Opened by
- Ben Jacobs - Anomaly Capital Management opened 3.9% of book
- Harry Burn - Sound Shore Management opened 2.6% of book
- Kahn Brothers Group opened 1.3% of book
- Robert Vinall - Rv Capital AG opened 1.1% of book
- John Paulson - Paulson & Co. opened 0.08% of book
- Lee Ainslie - Maverick Capital opened 0.07% of book
-
AVGO Broadcom Inc. 6 managers avg 0.21% of book · Stanley Druckenmiller - Duquesne Family Office, Ram Parameswaran - Octahedron Capital Management and 4 more
Opened by
- Stanley Druckenmiller - Duquesne Family Office opened 0.58% of book
- Ram Parameswaran - Octahedron Capital Management opened 0.53% of book
- Murphy Pohlad - Murphy Pohlad Asset Management opened 0.11% of book
- David Katz - Matrix Asset Advisors opened 0.03% of book
- Murray Stahl - Horizon Kinetics Asset Management opened <0.01% of book
- Bill Nygren / Oakmark - Harris Associates L P opened <0.01% of book
-
INTU Intuit 5 managers avg 2.7% of book · Mala Gaonkar - Surgocap Partners, Ben Jacobs - Anomaly Capital Management and 3 more
Opened by
- Mala Gaonkar - Surgocap Partners opened 8.0% of book
- Ben Jacobs - Anomaly Capital Management opened 4.4% of book
- Alex Sacerdote - Whale Rock Capital Management opened 0.95% of book
- Lee Ainslie - Maverick Capital opened 0.03% of book
- Bill Nygren / Oakmark - Harris Associates L P opened <0.01% of book
-
BLDR Builders Firstsource Inc. 5 managers avg 1.7% of book · Alex Roepers - Atlantic Investment Management, Gavin Baker - Atreides Management and 3 more
Opened by
- Alex Roepers - Atlantic Investment Management opened 7.1% of book
- Gavin Baker - Atreides Management opened 1.0% of book
- John Armitage - Egerton Capital (UK) opened 0.31% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.24% of book
- Ron Baron - Bamco Inc. (Baron Capital) opened 0.02% of book
-
UNH Unitedhealth Group, Inc. 5 managers avg 1.5% of book · Stephen Mandel - Lone Pine Capital, Samantha Mclemore - Patient Capital Management and 3 more
Opened by
- Stephen Mandel - Lone Pine Capital opened 3.8% of book
- Samantha Mclemore - Patient Capital Management opened 2.7% of book
- Warren Buffett - Berkshire Hathaway opened 0.61% of book
- Don Yacktman - Yacktman Asset Management opened 0.54% of book
- Tweedy, Browne Co. opened 0.03% of book
-
AMAT Applied Matls Inc. 5 managers avg 1.0% of book · Harry Burn - Sound Shore Management, Lewis Sanders - Sanders Capital and 3 more
Opened by
- Harry Burn - Sound Shore Management opened 2.3% of book
- Lewis Sanders - Sanders Capital opened 1.9% of book
- David Katz - Matrix Asset Advisors opened 0.95% of book
- Thomas Gayner - Markel Group opened 0.03% of book
- Bill Nygren / Oakmark - Harris Associates L P opened <0.01% of book
-
TMO Thermo Fisher Scientific Inc. 5 managers avg 0.56% of book · Glenview Capital Management, Robert Olstein - Olstein Capital Management and 3 more
Opened by
- Glenview Capital Management opened 1.1% of book
- Robert Olstein - Olstein Capital Management opened 0.61% of book
- First Pacific Advisors opened 0.51% of book
- Murphy Pohlad - Murphy Pohlad Asset Management opened 0.44% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.12% of book
Closed out by the most managers
-
UNH Unitedhealth Group, Inc. 6 managers was avg 2.8% of book · Mala Gaonkar - Surgocap Partners, Muhlenkamp & Co. and 4 more
Closed by
- Mala Gaonkar - Surgocap Partners closed was 7.0%
- Muhlenkamp & Co. closed was 4.3%
- Andreas Halvorsen - Viking Global Investors closed was 3.6%
- David Katz - Matrix Asset Advisors closed was 1.0%
- David Rolfe - Wedgewood Partners closed was 0.64%
- Ron Baron - Bamco Inc. (Baron Capital) closed was 0.09%
-
TTAN Servicetitan Inc. 5 managers was avg 0.27% of book · Chase Coleman - Tiger Global Management, Henry Ellenbogen - Durable Capital Partners and 3 more
Closed by
- Chase Coleman - Tiger Global Management closed was 0.47%
- Henry Ellenbogen - Durable Capital Partners closed was 0.44%
- Philippe Laffont - Coatue Management closed was 0.26%
- Lee Ainslie - Maverick Capital closed was 0.12%
- Brad Gerstner - Altimeter Capital Management closed was 0.08%
-
GOOGL / GOOG Alphabet 4 managers was avg 5.6% of book · Bill Ackman - Pershing Square, Alex Sacerdote - Whale Rock Capital Management and 2 more
Closed by
- Bill Ackman - Pershing Square closed was 14.0%
- Alex Sacerdote - Whale Rock Capital Management closed was 4.7%
- Rule One Partners closed was 3.8%
- Mason Hawkins - Southeastern Asset Management closed was 0.05%
-
Lgi Homes Lgi Homes Inc. 4 managers was avg 0.55% of book · Bryan Lawrence - Oakcliff Capital Partners, Ben Jacobs - Anomaly Capital Management and 2 more
Closed by
- Bryan Lawrence - Oakcliff Capital Partners closed was 1.8%
- Ben Jacobs - Anomaly Capital Management closed was 0.42%
- First Eagle Investment Management closed was 0.02%
- Polen Capital Management closed was <0.01%
-
JD Jd.com, Inc. 4 managers was avg 0.25% of book · Howard Marks - Oaktree Capital Management, George Soros - Soros Fund Management and 2 more
Closed by
- Howard Marks - Oaktree Capital Management closed was 0.76%
- George Soros - Soros Fund Management closed was 0.11%
- Ron Baron - Bamco Inc. (Baron Capital) closed was 0.11%
- Philippe Laffont - Coatue Management closed was 0.02%
-
CP Canadian Pacific Kansas City 3 managers was avg 6.2% of book · Bill Ackman - Pershing Square, Chris James - Meritage Group and 1 more
Closed by
- Bill Ackman - Pershing Square closed was 8.7%
- Chris James - Meritage Group closed was 7.3%
- Dan Sundheim - D1 Capital Partners closed was 2.5%
-
QSR Restaurant Brands Intl Inc. 3 managers was avg 4.4% of book · Bill Ackman - Pershing Square, Davidson Kempner Capital Management and 1 more
Closed by
- Bill Ackman - Pershing Square closed was 12.8%
- Davidson Kempner Capital Management closed was 0.18%
- Dan Sundheim - D1 Capital Partners closed was 0.09%
-
LLY Eli Lilly & Co. 3 managers was avg 3.5% of book · John Armitage - Egerton Capital (UK), Stephen Mandel - Lone Pine Capital and 1 more
Closed by
- John Armitage - Egerton Capital (UK) closed was 4.7%
- Stephen Mandel - Lone Pine Capital closed was 3.9%
- Senator Investment Group closed was 1.9%
-
META Meta Platforms Inc. 3 managers was avg 2.7% of book · Estuary Capital Management, Lee Ainslie - Maverick Capital and 1 more
Closed by
- Estuary Capital Management closed was 5.3%
- Lee Ainslie - Maverick Capital closed was 1.8%
- Ram Parameswaran - Octahedron Capital Management closed was 0.88%
-
MSFT Microsoft Corp. 3 managers was avg 2.4% of book · Gavin Baker - Atreides Management, Leon Cooperman - Omega Advisors and 1 more
Closed by
- Gavin Baker - Atreides Management closed was 4.8%
- Leon Cooperman - Omega Advisors closed was 1.6%
- Andreas Halvorsen - Viking Global Investors closed was 0.82%
Where the money went
Net bought by sector, with price moves taken out. Pick a sector to see its names.
- Health Care 12.2% weight · −0.3 pts +$7.8B 43 bought · 26 sold
- Materials 3.2% weight · +0.1 pts +$1.9B 15 bought · 17 sold
- Utilities 1.8% weight · −0.1 pts +$550M 9 bought · 15 sold
- Energy 4.3% weight · −0.3 pts −$355M 20 bought · 15 sold
- Consumer Discretionary 15.3% weight · no change −$1.6B 50 bought · 40 sold
- Consumer Staples 3.6% weight · −0.4 pts −$2B 12 bought · 27 sold
- Financials 17.8% weight · no change −$2.2B 42 bought · 51 sold
- Real Estate 3.3% weight · +0.5 pts −$2.7B 10 bought · 11 sold
- Information Technology 19.4% weight · +0.6 pts −$3.4B 35 bought · 48 sold
- Industrials 10.1% weight · +0.2 pts −$6.4B 35 bought · 39 sold
- Communication Services 9.0% weight · −0.2 pts −$8.1B 27 bought · 46 sold
Information Technology gained weight (+0.6 pts) even though managers sold $3.4B of it: weight follows price, not buying. Names without a sector (funds, foreign listings, private shares): +$3.2B.
Who moved the most
The biggest new positions, measured against each manager’s own book, and the managers that traded the most of theirs.
Biggest new bets
- Li Lu - Himalaya Capital Management opened PDD · Pdd Holdings Inc. 17.9% of book
- Norbert Lou - Punch Card Management opened CROX · Crocs Inc. 17.4% of book
- Eric Khrom - Khrom Capital Management opened AMCR · Amcor PLC 15.0% of book
- Farallon Capital Management opened SPY · Spdr S&P 500 ETF Tr 14.7% of book
- Grant Wonders - Voyager Global Management opened NVDA · Nvidia Corporation 12.2% of book
- Dennis Hong - Shawspring Partners opened OKTA · Okta Inc. 12.0% of book
Most active managers
- Josh Kushner - Thrive Capital Management 0 opened · 0 closed · −$688M net 117% of book traded
- Ben Jacobs - Anomaly Capital Management 14 opened · 10 closed · +$724M net 112% of book traded
- Bill Ackman - Pershing Square 0 opened · 9 closed · −$12.8B net 108% of book traded
- Gavin Baker - Atreides Management 15 opened · 10 closed · −$189M net 104% of book traded
- Estuary Capital Management 5 opened · 6 closed · +$94M net 102% of book traded
- Spencer Waxman - Shannon River Fund Management 10 opened · 1 closed · +$231M net 100% of book traded
What they hold
Most owned counts managers, with the change since last quarter. Largest is the share of the combined book, each manager counting once. Highest conviction is the average position among holders, three or more.
Most owned
- 1 GOOGL / GOOG Alphabet 67 managers +2
- 2 MSFT Microsoft Corp. 63 managers no change
- 3 AMZN Amazon.com, Inc. 53 managers +2
- 4 META Meta Platforms Inc. 50 managers +3
- 5 TSM Taiwan Semiconductor Mfg Ltd 39 managers +1
- 6 BRK.B / BRK.A Berkshire Hathaway 36 managers −1
- 7 NVDA Nvidia Corporation 35 managers +5
- 8 V Visa Inc. 34 managers no change
- 9 AAPL Apple Inc. 31 managers +2
- 10 MA Mastercard Inc. 28 managers no change
Largest
- 1 MSFT Microsoft Corp. 2.8% held by 63
- 2 GOOGL / GOOG Alphabet 2.6% held by 67
- 3 BRK.B / BRK.A Berkshire Hathaway 2.4% held by 36
- 4 AMZN Amazon.com, Inc. 2.1% held by 53
- 5 META Meta Platforms Inc. 1.9% held by 50
- 6 CVNA Carvana Co. 1.5% held by 12
- 7 TSM Taiwan Semiconductor Mfg Ltd 0.99% held by 39
- 8 NVDA Nvidia Corporation 0.98% held by 35
- 9 AAPL Apple Inc. 0.93% held by 31
- 10 V Visa Inc. 0.89% held by 34
Highest conviction
- 1 HHH Howard Hughes Holdings Inc. avg 26.6% held by 4
- 2 CVNA Carvana Co. avg 17.2% held by 12
- 3 LOAR Loar Holdings Inc. avg 15.2% held by 3
- 4 VAL Valaris Ltd avg 11.8% held by 3
- 5 MDGL Madrigal Pharmaceuticals Inc. avg 10.9% held by 3
- 6 OSCR Oscar Health Inc. avg 9.9% held by 6
- 7 TDG Transdigm Group Inc. avg 9.9% held by 6
- 8 SNX Td Synnex Corporation avg 9.5% held by 6
- 9 BRK.B / BRK.A Berkshire Hathaway avg 9.0% held by 36
- 10 SWX Southwest Gas Holdings Inc. avg 8.4% held by 3
Did the combined book beat SPY?
Each quarter’s combined book held to the next quarter-end, at the 13Fs’ own prices. Price only, no dividends, and today’s managers throughout. Nobody could have copied it: 13Fs arrive about 45 days after the quarter ends.
Combined book, 8 quarters
+44.2%
SPY
+37.2%
Difference
+6.9 pts
2024 Q2, the start
+0.0% Combined book
+0.0% SPY
2024 Q3, since 2024 Q2
+7.5% Combined book
+5.4% SPY
That quarter: book +7.5%, SPY +5.4%
2024 Q4, since 2024 Q2
+10.2% Combined book
+7.7% SPY
That quarter: book +2.6%, SPY +2.1%
2025 Q1, since 2024 Q2
+6.0% Combined book
+2.8% SPY
That quarter: book −3.8%, SPY −4.6%
2025 Q2, since 2024 Q2
+18.3% Combined book
+13.5% SPY
That quarter: book +11.6%, SPY +10.5%
2025 Q3, since 2024 Q2
+29.0% Combined book
+22.4% SPY
That quarter: book +9.1%, SPY +7.8%
2025 Q4, since 2024 Q2
+31.8% Combined book
+25.3% SPY
That quarter: book +2.1%, SPY +2.4%
2026 Q1, since 2024 Q2
+25.9% Combined book
+19.5% SPY
That quarter: book −4.4%, SPY −4.6%
2026 Q2, since 2024 Q2
+44.2% Combined book
+37.2% SPY
That quarter: book +14.5%, SPY +14.8%
Quarter by quarter
| Quarter | Each manager once | By dollars | SPY | Book − SPY | Managers |
|---|---|---|---|---|---|
| 2026 Q2 | +14.5% | +11.5% | +14.8% | −0.4 pts | 133 |
| 2026 Q1 | −4.4% | −4.2% | −4.6% | +0.2 pts | 136 |
| 2025 Q4 | +2.1% | +2.6% | +2.4% | −0.2 pts | 136 |
| 2025 Q3 | +9.1% | +6.3% | +7.8% | +1.2 pts | 136 |
| 2025 Q2 | +11.6% | +8.0% | +10.5% | +1.1 pts | 136 |
| 2025 Q1 | −3.8% | −2.0% | −4.6% | +0.7 pts | 136 |
| 2024 Q4 | +2.6% | +1.1% | +2.1% | +0.4 pts | 134 |
| 2024 Q3 | +7.5% | +6.9% | +5.4% | +2.1 pts | 133 |
All 2,503 names
Download CSVShowing 300 of 367 matching names. The CSV has every name.
| Ticker | Company | Sector | Held by | Weight | Net bought | Bought / sold | Opened / closed |
|---|---|---|---|---|---|---|---|
| UNH | Unitedhealth Group, Inc. | Health Care | 28 −1 | 0.43% | +$4.1B | 21 / 12 | 5 / 6 |
| DHR | Danaher Corporation | Health Care | 20 +2 | 0.26% | +$579M | 9 / 5 | 4 / 2 |
| TMO | Thermo Fisher Scientific Inc. | Health Care | 19 +4 | 0.20% | +$197M | 13 / 4 | 5 / 1 |
| JNJ | Johnson & Johnson | Health Care | 16 +1 | 0.13% | −$68M | 2 / 3 | 1 / 0 |
| LLY | Eli Lilly & Co. | Health Care | 15 +1 | 0.12% | −$186M | 7 / 4 | 4 / 3 |
| CVS | Cvs Health Corp. | Health Care | 14 +1 | 0.39% | −$694M | 2 / 6 | 1 / 0 |
| ELV | Elevance Health Inc. | Health Care | 14 | 0.31% | +$260M | 5 / 3 | 0 / 0 |
| PFE | Pfizer Inc. | Health Care | 12 −1 | 0.12% | +$11M | 3 / 3 | 0 / 1 |
| MRK | Merck & Co. Inc. | Health Care | 12 | 0.09% | +$138M | 6 / 2 | 1 / 1 |
| ABT | Abbott Labs | Health Care | 12 +1 | 0.08% | −$2M | 2 / 3 | 1 / 0 |
| ZTS | Zoetis Inc. | Health Care | 11 +2 | 0.12% | −$28M | 4 / 3 | 2 / 0 |
| BMY | Bristol-Myers Squibb Co. | Health Care | 11 −1 | 0.09% | −$216M | 4 / 4 | 1 / 2 |
| ZBH | Zimmer Biomet Holdings, Inc. | Health Care | 11 +1 | 0.08% | +$557M | 4 / 4 | 1 / 0 |
| ABBV | Abbvie Inc. | Health Care | 11 | 0.03% | −$1M | 3 / 1 | 1 / 1 |
| CI | The Cigna Group | Health Care | 10 | 0.14% | −$286M | 2 / 4 | 1 / 1 |
| MDT | Medtronic PLC | Health Care | 10 | 0.10% | −$5M | 2 / 2 | 0 / 0 |
| ICLR | Icon PLC | Health Care | 10 +3 | 0.07% | +$419M | 5 / 1 | 3 / 0 |
| GEHC | Ge Healthcare Technologies, Inc. | Health Care | 10 +1 | 0.05% | +$903M | 5 / 2 | 1 / 0 |
| HCA | Hca Healthcare Inc. | Health Care | 9 −1 | 0.18% | −$135M | 3 / 6 | 0 / 1 |
| TEVA | Teva Pharmaceutical Inds Ltd | Health Care | 9 +1 | 0.18% | +$201M | 9 / 0 | 1 / 0 |
| WST | Western Alliance Bancorp | Health Care | 9 +1 | 0.12% | −$158M | 3 / 3 | 1 / 0 |
| BAX | Baxter International, Inc. | Health Care | 9 | 0.09% | +$107M | 1 / 2 | 0 / 0 |
| NTRA | Natera Inc. | Health Care | 8 +1 | 0.21% | −$19M | 3 / 2 | 1 / 0 |
| BSX | Boston Scientific Corp. | Health Care | 8 | 0.17% | +$260M | 4 / 3 | 1 / 1 |
| ILMN | Illumina Inc. | Health Care | 8 | 0.16% | +$22M | 5 / 2 | 1 / 1 |
| GSK | Gsk PLC | Health Care | 8 +1 | 0.12% | −$3M | 1 / 2 | 1 / 0 |
| BDX | Becton Dickinson & Co. | Health Care | 8 −1 | 0.12% | +$936M | 4 / 3 | 0 / 1 |
| CAH | Cardinal Health Inc. | Health Care | 8 +2 | 0.10% | +$23M | 3 / 3 | 2 / 0 |
| IQV | Iqvia Hldgs Inc. | Health Care | 8 +3 | 0.08% | +$258M | 5 / 3 | 3 / 0 |
| AMGN | Amgen Inc. | Health Care | 8 | 0.05% | +$5M | 2 / 0 | 0 / 0 |
| NVO | Novo-Nordisk A S | Health Care | 8 +1 | 0.02% | −$26M | 2 / 2 | 1 / 0 |
| THC | Tenet Healthcare Corp. | Health Care | 7 | 0.22% | +$30M | 3 / 3 | 1 / 1 |
| SYK | Stryker Corporation | Health Care | 7 +1 | 0.11% | −$196M | 1 / 3 | 1 / 0 |
| NVS | Novartis AG | Health Care | 7 +1 | 0.02% | −$143M | 1 / 3 | 1 / 0 |
| OSCR | Oscar Health Inc. | Health Care | 6 +1 | 0.44% | −$126M | 3 / 3 | 2 / 1 |
| INSM | Insmed Inc. | Health Care | 6 −1 | 0.19% | +$77M | 2 / 4 | 0 / 1 |
| MCK | Mckesson Corp. | Health Care | 6 | 0.13% | −$243M | 2 / 5 | 1 / 1 |
| IDXX | Idexx Labs Inc. | Health Care | 6 | 0.09% | +$427M | 2 / 1 | 1 / 1 |
| REGN | Regeneron Pharmaceuticals, Inc. | Health Care | 6 −1 | 0.05% | +$750M | 3 / 3 | 1 / 2 |
| SNY | Sanofi SA | Health Care | 6 | 0.05% | −$65M | 1 / 1 | 0 / 0 |
| VEEV | Veeva Sys Inc. | Health Care | 6 +1 | 0.04% | +$276M | 1 / 3 | 1 / 0 |
| ALKS | Alkermes PLC | Health Care | 6 +1 | 0.04% | −$20M | 2 / 1 | 1 / 0 |
| ISRG | Intuitive Surgical Inc. | Health Care | 6 +1 | 0.03% | +$19M | 2 / 1 | 1 / 0 |
| DGX | Quest Diagnostics Inc. | Health Care | 6 −1 | 0.02% | −$208M | 0 / 4 | 0 / 1 |
| SOLV | Solventum Corporation | Health Care | 5 −1 | 0.14% | −$61M | 1 / 2 | 0 / 1 |
| ACHC | Acadia Healthcare Company In | Health Care | 5 | 0.14% | +$97M | 5 / 0 | 0 / 0 |
| BIIB | Biogen Inc. | Health Care | 5 | 0.08% | −$10M | 1 / 1 | 0 / 0 |
| HUM | Humana, Inc. | Health Care | 5 −1 | 0.06% | −$264M | 2 / 3 | 0 / 1 |
| VTRS | Viatris Inc. | Health Care | 5 | 0.06% | −$43M | 1 / 1 | 1 / 1 |
| HSIC | Henry Schein Inc. | Health Care | 5 +1 | 0.05% | +$103M | 2 / 1 | 1 / 0 |
| VRTX | Vertex Pharmaceuticals | Health Care | 5 | 0.04% | +$6M | 2 / 2 | 0 / 0 |
| CNC | Centene Corp. Del | Health Care | 5 | 0.04% | −$106M | 2 / 3 | 1 / 1 |
| BNTX | Biontech Se | Health Care | 5 | 0.04% | −$2M | 1 / 4 | 1 / 1 |
| MEDP | Medpace Hldgs Inc. | Health Care | 5 −1 | 0.04% | −$6M | 1 / 3 | 0 / 1 |
| TECH | Bio-Techne Corp. | Health Care | 5 −1 | 0.03% | −$42M | 1 / 3 | 1 / 2 |
| ALGN | Align Technology Inc. | Health Care | 5 | 0.02% | +$212K | 0 / 1 | 0 / 0 |
| HQY | Healthequity Inc. | Health Care | 5 +2 | 0.02% | +$14M | 3 / 1 | 2 / 0 |
| UHS | Universal Hlth Svcs Inc. | Health Care | 4 | 0.10% | −$66M | 1 / 1 | 0 / 0 |
| RVMD | Revolution Medicines Inc. | Health Care | 4 +1 | 0.09% | +$34M | 3 / 0 | 1 / 0 |
| WAT | Waters Corp. | Health Care | 4 | 0.07% | −$36M | 1 / 1 | 0 / 0 |
| RPRX | Royalty Pharma PLC | Health Care | 4 −1 | 0.07% | −$295M | 1 / 3 | 0 / 1 |
| BIO | Bio Rad Labs Inc. | Health Care | 4 | 0.06% | +$254M | 2 / 0 | 0 / 0 |
| A | Agilent Technologies Inc. | Health Care | 4 | 0.05% | −$13M | 0 / 1 | 0 / 0 |
| NVST | Envista Holdings Corporation | Health Care | 4 | 0.04% | −$10M | 1 / 1 | 0 / 0 |
| BBIO | Bridgebio Pharma Inc. | Health Care | 4 | 0.04% | −$72M | 3 / 2 | 1 / 1 |
| HOLX | Hologic, Inc. | Health Care | 4 | 0.03% | +$2M | 2 / 1 | 1 / 1 |
| MTD | Mettler Toledo International | Health Care | 4 | 0.03% | −$50M | 0 / 1 | 0 / 0 |
| COR | Cencora Inc. | Health Care | 4 −1 | 0.03% | +$302M | 1 / 3 | 0 / 1 |
| EW | Edwards Lifesciences Corp. | Health Care | 4 | 0.03% | +$679K | 1 / 2 | 0 / 0 |
| SNDX | Syndax Pharmaceuticals Inc. | Health Care | 4 | 0.02% | −$7M | 0 / 1 | 0 / 0 |
| GILD | Gilead Sciences, Inc. | Health Care | 4 | 0.02% | −$214M | 2 / 3 | 1 / 1 |
| EHC | Encompass Health Corp. | Health Care | 4 +2 | 0.02% | +$21M | 3 / 1 | 2 / 0 |
| AXSM | Axsome Therapeutics Inc. | Health Care | 4 +1 | 0.02% | +$2M | 2 / 0 | 1 / 0 |
| DOCS | Doximity Inc. | Health Care | 4 +2 | <0.01% | +$8M | 3 / 1 | 2 / 0 |
| CAI | Caris Life Sciences Inc. IPO or spin-off | Health Care | 4 +4 | <0.01% | +$275M | 4 / 0 | 4 / 0 |
| PGNY | Progyny Inc. | Health Care | 4 | <0.01% | −$5M | 1 / 2 | 0 / 0 |
| MDGL | Madrigal Pharmaceuticals Inc. | Health Care | 3 +1 | 0.24% | +$3M | 1 / 0 | 1 / 0 |
| UTHR | United Therapeutics Corp. | Health Care | 3 −1 | 0.16% | −$7M | 1 / 2 | 0 / 1 |
| EXEL | Exelixis Inc. | Health Care | 3 | 0.11% | −$303M | 1 / 2 | 0 / 0 |
| SGRY | Surgery Partners Inc. | Health Care | 3 +2 | 0.11% | +$104M | 3 / 0 | 2 / 0 |
| NVAX | Novavax Inc. | Health Care | 3 | 0.10% | +$2M | 1 / 0 | 0 / 0 |
| BHC | Bausch Health Companies Inc. | Health Care | 3 | 0.10% | +$42M | 1 / 0 | 0 / 0 |
| BMRN | Biomarin Pharmaceutical, Inc. | Health Care | 3 −1 | 0.09% | −$110M | 1 / 2 | 0 / 1 |
| WGS | Genedx Holdings Corp. | Health Care | 3 +1 | 0.09% | +$64M | 3 / 0 | 1 / 0 |
| IONS | Ionis Pharmaceuticals Inc. | Health Care | 3 −1 | 0.08% | −$10M | 0 / 3 | 0 / 1 |
| ALC | Alcon AG | Health Care | 3 | 0.08% | +$182M | 3 / 0 | 0 / 0 |
| CGON | Cg Oncology Inc. | Health Care | 3 +1 | 0.07% | +$16M | 3 / 0 | 1 / 0 |
| INSP | Inspire Med Sys Inc. | Health Care | 3 | 0.05% | +$146M | 2 / 0 | 0 / 0 |
| ALNY | Alnylam Pharmaceuticals, Inc. | Health Care | 3 −1 | 0.04% | −$73M | 0 / 2 | 0 / 1 |
| DXCM | Dexcom Inc. | Health Care | 3 | 0.04% | −$6M | 1 / 1 | 0 / 0 |
| SHC | Sotera Health Co. | Health Care | 3 | 0.04% | +$13M | 2 / 1 | 1 / 1 |
| CRSP | Crispr Therapeutics AG | Health Care | 3 +1 | 0.03% | +$3M | 1 / 0 | 1 / 0 |
| ASND | Ascendis Pharma A/S | Health Care | 3 | 0.03% | −$28M | 1 / 2 | 1 / 1 |
| ROIV | Roivant Sciences Ltd | Health Care | 3 | 0.02% | −$143M | 0 / 2 | 0 / 0 |
| INCY | Incyte Corp. | Health Care | 3 | 0.02% | −$43M | 0 / 2 | 0 / 0 |
| BEAM | Beam Therapeutics Inc. | Health Care | 3 | 0.02% | +$3M | 0 / 1 | 0 / 0 |
| NBIX | Neurocrine Biosciences, Inc. | Health Care | 3 −2 | 0.02% | −$37M | 0 / 2 | 0 / 2 |
| XENE | Xenon Pharmaceuticals Inc. | Health Care | 3 | 0.02% | −$5M | 1 / 2 | 0 / 0 |
| LH | Labcorp Holdings Inc. | Health Care | 3 | 0.02% | −$4M | 0 / 1 | 0 / 0 |
| STOK | Stoke Therapeutics Inc. | Health Care | 3 | 0.02% | +$4M | 2 / 0 | 0 / 0 |
| CRL | Charles Riv Labs Intl Inc. | Health Care | 3 | 0.02% | +$104M | 2 / 2 | 1 / 1 |
| RGEN | Repligen Corp. | Health Care | 3 +1 | 0.02% | +$18M | 2 / 1 | 1 / 0 |
| PTGX | Protagonist Therapeutics Inc. | Health Care | 3 +1 | 0.02% | +$4M | 1 / 0 | 1 / 0 |
| AVTR | Avantor, Inc. | Health Care | 3 −2 | 0.02% | +$171M | 3 / 3 | 1 / 3 |
| AXGN | Axogen Inc. | Health Care | 3 +1 | 0.02% | +$3M | 3 / 0 | 1 / 0 |
| MOH | Molina Healthcare Inc. | Health Care | 3 +1 | 0.02% | +$225M | 2 / 0 | 1 / 0 |
| Masimo | Masimo Corp. | Health Care | 3 +1 | 0.01% | +$147M | 2 / 0 | 1 / 0 |
| BLCO | Bausch Plus Lomb Corp. | Health Care | 3 +1 | 0.01% | +$47M | 2 / 0 | 1 / 0 |
| RARE | Ultragenyx Pharmaceutical In | Health Care | 3 +1 | 0.01% | +$25M | 2 / 2 | 2 / 1 |
| FMS | Fresenius Medical Care AG | Health Care | 3 | 0.01% | −$30M | 0 / 2 | 0 / 0 |
| URGN | Urogen Pharma Ltd | Health Care | 3 | 0.01% | −$2M | 0 / 2 | 0 / 0 |
| ADPT | Adaptive Biotechnologies Cor | Health Care | 3 +1 | <0.01% | −$42M | 1 / 1 | 1 / 0 |
| DNA | Ginkgo Bioworks Holdings Inc. | Health Care | 3 | <0.01% | −$8M | 0 / 2 | 0 / 0 |
| NAMS | Newamsterdam Pharma Company | Health Care | 3 −1 | <0.01% | +$17M | 1 / 1 | 0 / 1 |
| GH | Guardant Health Inc. | Health Care | 3 +2 | <0.01% | +$75M | 3 / 0 | 2 / 0 |
| COO | Cooper Cos Inc. | Health Care | 3 +1 | <0.01% | +$20M | 1 / 0 | 1 / 0 |
| VKTX | Viking Therapeutics Inc. | Health Care | 3 +1 | <0.01% | +$7M | 1 / 1 | 1 / 0 |
| SDGR | Schrodinger Inc. | Health Care | 3 +1 | <0.01% | +$16M | 1 / 1 | 1 / 0 |
| BFLY | Butterfly Network Inc. | Health Care | 3 +1 | <0.01% | −$946K | 1 / 1 | 1 / 0 |
| BTI | British Amern Tob PLC | Health Care | 3 | <0.01% | +$2M | 1 / 1 | 0 / 0 |
| BCYC | Bicycle Therapeutics Plc-Adr | Health Care | 3 | <0.01% | −$118K | 0 / 1 | 0 / 0 |
| NUVB | Nuvation Bio Inc. | Health Care | 3 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CDNA | Caredx Inc. | Health Care | 3 | <0.01% | +$954K | 2 / 1 | 0 / 0 |
| EMBC | Embecta Corp. | Health Care | 3 +1 | <0.01% | +$297K | 1 / 0 | 1 / 0 |
| Compugen | Compugen Ltd | Health Care | 3 | <0.01% | +$305K | 1 / 0 | 0 / 0 |
| RDNT | Radnet Inc. | Health Care | 3 +1 | <0.01% | +$8M | 2 / 1 | 1 / 0 |
| GRAL | Grail Inc. | Health Care | 3 +2 | <0.01% | +$27M | 2 / 0 | 2 / 0 |
| BKD | Brookdale Sr Living Inc. | Health Care | 3 | <0.01% | −$9M | 1 / 1 | 1 / 1 |
| JAZZ | Jazz Pharmaceuticals PLC | Health Care | 2 −1 | 0.13% | +$12M | 2 / 1 | 0 / 1 |
| INDV | Indivior PLC | Health Care | 2 | 0.08% | +$134K | 0 / 0 | 0 / 0 |
| SUPN | Supernus Pharmaceuticals Inc. | Health Care | 2 | 0.07% | +$1M | 1 / 0 | 0 / 0 |
| ENTA | Enanta Pharmaceuticals Inc. | Health Care | 2 | 0.06% | −$16K | 0 / 0 | 0 / 0 |
| OGN | Organon & Co. | Health Care | 2 −1 | 0.06% | −$38M | 2 / 1 | 0 / 1 |
| ENOV | Enovis Corporation | Health Care | 2 | 0.05% | +$70M | 1 / 1 | 1 / 1 |
| FOLD | Amicus Therapeutics Inc. | Health Care | 2 | 0.05% | −$10M | 0 / 1 | 0 / 0 |
| LQDA | Liquidia Corporation | Health Care | 2 | 0.05% | +$6M | 2 / 0 | 0 / 0 |
| TGTX | Tg Therapeutics Inc. | Health Care | 2 +1 | 0.03% | +$532K | 1 / 0 | 1 / 0 |
| IRON | Disc Medicine Inc. | Health Care | 2 +1 | 0.03% | +$13M | 2 / 0 | 1 / 0 |
| Perrigo | Perrigo Company PLC | Health Care | 2 | 0.02% | −$80K | 0 / 0 | 0 / 0 |
| ARVN | Arvinas Inc. | Health Care | 2 | 0.02% | −$3M | 0 / 2 | 0 / 0 |
| AGIO | Agios Pharmaceuticals Inc. | Health Care | 2 | 0.02% | +$2M | 0 / 0 | 0 / 0 |
| LRMR | Larimar Therapeutics Inc. | Health Care | 2 | 0.02% | +$6M | 1 / 0 | 0 / 0 |
| LNTH | Lantheus Hldgs Inc. | Health Care | 2 | 0.02% | +$57M | 1 / 0 | 0 / 0 |
| VNDA | Vanda Pharmaceuticals Inc. | Health Care | 2 | 0.02% | +$1M | 1 / 0 | 0 / 0 |
| OPCH | Option Care Health Inc. | Health Care | 2 +1 | 0.02% | +$174M | 2 / 0 | 1 / 0 |
| AVAH | Aveanna Healthcare Hldgs Inc. | Health Care | 2 | 0.02% | −$8M | 1 / 1 | 0 / 0 |
| PBH | Prestige Consmr Healthcare I | Health Care | 2 −1 | 0.02% | −$26M | 0 / 3 | 0 / 1 |
| EWTX | Edgewise Therapeutics Inc. | Health Care | 2 −1 | 0.02% | −$4M | 2 / 1 | 0 / 1 |
| MMSI | Merit Med Sys Inc. | Health Care | 2 | 0.01% | +$10M | 1 / 0 | 0 / 0 |
| DVA | Davita Inc. | Health Care | 2 | 0.01% | −$192M | 0 / 0 | 0 / 0 |
| HIMS | Hims & Hers Health Inc. | Health Care | 2 +1 | 0.01% | +$14M | 1 / 0 | 1 / 0 |
| TWST | Twist Bioscience Corp. | Health Care | 2 | 0.01% | +$6M | 0 / 0 | 0 / 0 |
| LKFT | Galapagos NV | Health Care | 2 | 0.01% | $0 | 0 / 0 | 0 / 0 |
| DNLI | Denali Therapeutics Inc. | Health Care | 2 +1 | 0.01% | +$4M | 2 / 0 | 1 / 0 |
| IOVA | Iovance Biotherapeutics Inc. | Health Care | 2 | <0.01% | +$375K | 1 / 0 | 0 / 0 |
| FTRE | Fortrea Hldgs Inc. | Health Care | 2 | <0.01% | −$14M | 0 / 1 | 0 / 0 |
| PODD | Insulet Corp. | Health Care | 2 +1 | <0.01% | +$1M | 1 / 1 | 1 / 0 |
| IMVT | Immunovant Inc. | Health Care | 2 −1 | <0.01% | −$17M | 1 / 1 | 0 / 1 |
| VCYT | Veracyte Inc. | Health Care | 2 | <0.01% | −$4M | 0 / 0 | 0 / 0 |
| ARQT | Arcutis Biotherapeutics Inc. | Health Care | 2 +1 | <0.01% | +$4M | 1 / 0 | 1 / 0 |
| PHG | Koninklijke Philips NV | Health Care | 2 | <0.01% | +$8M | 2 / 0 | 0 / 0 |
| MIRM | Mirum Pharmaceuticals Inc. | Health Care | 2 | <0.01% | −$1M | 1 / 1 | 1 / 1 |
| CMPS | Compass Pathways PLC | Health Care | 2 | <0.01% | −$156K | 1 / 1 | 0 / 0 |
| ITGR | Integer Hldgs Corp. | Health Care | 2 −1 | <0.01% | +$10M | 2 / 1 | 0 / 1 |
| QURE | Uniqure NV | Health Care | 2 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| ORIC | Oric Pharmaceuticals Inc. | Health Care | 2 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| ALMS | Alumis Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$3M | 2 / 0 | 2 / 0 |
| DYN | Dyne Therapeutics Inc. | Health Care | 2 −1 | <0.01% | −$2M | 0 / 2 | 0 / 1 |
| SPRY | Ars Pharmaceuticals Inc. | Health Care | 2 +1 | <0.01% | +$1M | 2 / 1 | 2 / 1 |
| BWAY | Brainsway Ltd | Health Care | 2 | <0.01% | −$235K | 1 / 1 | 0 / 0 |
| LXEO | Lexeo Therapeutics Inc. | Health Care | 2 −1 | <0.01% | −$3M | 0 / 1 | 0 / 1 |
| XRAY | Dentsply Sirona Inc. | Health Care | 2 −1 | <0.01% | −$17M | 1 / 1 | 0 / 1 |
| TRVI | Trevi Therapeutics Inc. | Health Care | 2 | <0.01% | −$11M | 0 / 2 | 0 / 0 |
| ALLO | Allogene Therapeutics Inc. | Health Care | 2 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TVTX | Travere Therapeutics Inc. | Health Care | 2 | <0.01% | −$38M | 1 / 1 | 1 / 1 |
| KPTI | Karyopharm Therapeutics Inc. | Health Care | 2 +1 | <0.01% | +$810K | 1 / 0 | 1 / 0 |
| WAY | Waystar Hldg Corp. | Health Care | 2 | <0.01% | −$56M | 1 / 1 | 0 / 0 |
| ELVN | Enliven Therapeutics Inc. | Health Care | 2 +1 | <0.01% | +$9M | 1 / 0 | 1 / 0 |
| BBNX | Beta Bionics Inc. | Health Care | 2 −1 | <0.01% | +$12M | 1 / 1 | 0 / 1 |
| SRTA | Blade Air Mobility Inc. | Health Care | 2 | <0.01% | +$3M | 2 / 0 | 0 / 0 |
| ALVO | Alvotech SA | Health Care | 2 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| TMDX | Transmedics Group Inc. | Health Care | 2 | <0.01% | +$6M | 2 / 1 | 1 / 1 |
| KRYS | Krystal Biotech | Health Care | 2 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| SION | Sionna Therapeutics Inc. | Health Care | 2 +1 | <0.01% | +$5M | 2 / 0 | 1 / 0 |
| ESTA | Establishment Labs Hldgs Inc. | Health Care | 2 +1 | <0.01% | +$22M | 2 / 0 | 1 / 0 |
| ALT | Altimmune Inc. | Health Care | 2 +1 | <0.01% | +$406K | 1 / 0 | 1 / 0 |
| PEPG | Pepgen Inc. | Health Care | 2 | <0.01% | −$200K | 0 / 1 | 0 / 0 |
| PRME | Prime Medicine Inc. | Health Care | 2 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| GRFS | Grifols S A | Health Care | 2 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| PNTG | Pennant Group Inc. | Health Care | 2 +1 | <0.01% | +$193K | 1 / 0 | 1 / 0 |
| ATEC | Alphatec Hldgs Inc. | Health Care | 2 +1 | <0.01% | +$357K | 1 / 0 | 1 / 0 |
| LIVN | Livanova PLC | Health Care | 2 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| HROW | Harrow Health Inc. | Health Care | 1 | 0.18% | −$2M | 0 / 1 | 0 / 0 |
| ACAD | Acadia Pharmaceuticals Inc. | Health Care | 1 −1 | 0.09% | −$6M | 0 / 2 | 0 / 1 |
| LFCR | Lifecore Biomedical Inc. | Health Care | 1 | 0.08% | +$639K | 0 / 0 | 0 / 0 |
| ETON | Eton Pharmaceuticals Inc. | Health Care | 1 | 0.06% | +$113K | 0 / 0 | 0 / 0 |
| STXS | Stereotaxis Inc. | Health Care | 1 | 0.06% | $0 | 0 / 0 | 0 / 0 |
| DNTH | Dianthus Therapeutics Inc. | Health Care | 1 | 0.05% | +$410K | 0 / 0 | 0 / 0 |
| SNWV | Sanuwave Health Inc. | Health Care | 1 | 0.05% | +$263K | 0 / 0 | 0 / 0 |
| RYTM | Rhythm Pharmaceuticals Inc. | Health Care | 1 | 0.04% | −$948K | 0 / 0 | 0 / 0 |
| ATRC | Atricure Inc. | Health Care | 1 | 0.04% | $0 | 0 / 0 | 0 / 0 |
| Bausch Lomb | Bausch Lomb Corp. | Health Care | 1 | 0.03% | −$2M | 0 / 1 | 0 / 0 |
| ANAB | Anaptysbio Inc. | Health Care | 1 −1 | 0.03% | −$10M | 0 / 2 | 0 / 1 |
| NVCR | Novocure Ltd | Health Care | 1 −1 | 0.03% | −$12M | 0 / 1 | 0 / 1 |
| CYTK | Cytokinetics Inc. | Health Care | 1 −1 | 0.03% | −$7M | 0 / 1 | 0 / 1 |
| IDYA | Ideaya Biosciences Inc. | Health Care | 1 −1 | 0.03% | −$9M | 1 / 1 | 0 / 1 |
| OCUL | Ocular Therapeutix Inc. | Health Care | 1 | 0.02% | $0 | 0 / 0 | 0 / 0 |
| GMAB | Genmab A/S | Health Care | 1 +1 | 0.02% | +$13M | 1 / 0 | 1 / 0 |
| JBIO | Jade Biosciences Inc. IPO or spin-off | Health Care | 1 +1 | 0.02% | +$11M | 1 / 0 | 1 / 0 |
| PHAT | Phathom Pharmaceuticals Inc. | Health Care | 1 | 0.01% | +$3M | 1 / 0 | 0 / 0 |
| PRVA | Privia Health Group Inc. | Health Care | 1 | 0.01% | $0 | 0 / 0 | 0 / 0 |
| Kalvista Pharmaceutic… | Kalvista Pharmaceuticals Inc. | Health Care | 1 | 0.01% | −$2M | 0 / 1 | 0 / 0 |
| PRTA | Prothena Corp. PLC | Health Care | 1 | 0.01% | −$2M | 0 / 1 | 0 / 0 |
| TNDM | Tandem Diabetes Care Inc. | Health Care | 1 | 0.01% | $0 | 0 / 0 | 0 / 0 |
| RCUS | Arcus Biosciences Inc. | Health Care | 1 | 0.01% | +$20K | 0 / 0 | 0 / 0 |
| MLYS | Mineralys Therapeutics Inc. | Health Care | 1 | 0.01% | +$843K | 1 / 0 | 0 / 0 |
| XOMA | Xoma Corp. Del | Health Care | 1 | <0.01% | +$52K | 0 / 0 | 0 / 0 |
| CATX | Perspective Therapeutics Inc. | Health Care | 1 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| ANIK | Anika Therapeutics Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| COLL | Collegium Pharmaceutical Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| RXRX | Recursion Pharmaceuticals Inc. | Health Care | 1 | <0.01% | −$9M | 0 / 1 | 0 / 0 |
| INGN | Inogen Inc. | Health Care | 1 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
| PGEN | Precigen Inc. | Health Care | 1 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| LZAGY | Lonza Group Adr | Health Care | 1 | <0.01% | −$427K | 0 / 1 | 0 / 0 |
| Enhabit | Enhabit Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CNTX | Context Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| BHVN | Biohaven Ltd | Health Care | 1 −3 | <0.01% | −$70M | 1 / 3 | 0 / 3 |
| PRQR | Proqr Therapeutics N V | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| BCAX | Bicara Therapeutics Inc. | Health Care | 1 | <0.01% | +$975K | 1 / 0 | 0 / 0 |
| RZLT | Rezolute Inc. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| WVE | Wave Life Sciences Ltd | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ORKA | Oruka Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TELA | Tela Bio Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| KURA | Kura Oncology Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| MYGN | Myriad Genetics Inc. | Health Care | 1 | <0.01% | +$4M | 1 / 0 | 0 / 0 |
| ELAN | Elanco Animal Health, Inc. | Health Care | 1 −1 | <0.01% | −$590K | 0 / 1 | 0 / 1 |
| PCVX | Vaxcyte Inc. | Health Care | 1 −1 | <0.01% | +$3M | 1 / 1 | 0 / 1 |
| TSHA | Taysha Gene Therapies Inc. | Health Care | 1 −1 | <0.01% | −$2M | 0 / 2 | 0 / 1 |
| CRNX | Crinetics Pharmaceuticals In | Health Care | 1 | <0.01% | +$1M | 0 / 0 | 0 / 0 |
| APGE | Apogee Therapeutics Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$3M | 1 / 0 | 1 / 0 |
| MBX | Mbx Biosciences Inc. | Health Care | 1 | <0.01% | −$122K | 0 / 0 | 0 / 0 |
| BCRX | Biocryst Pharmaceuticals Inc. | Health Care | 1 | <0.01% | −$3M | 0 / 1 | 0 / 0 |
| ARAY | Accuray Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ZNTL | Zentalis Pharmaceuticals Inc. | Health Care | 1 | <0.01% | −$70K | 0 / 0 | 0 / 0 |
| ACRS | Aclaris Therapeutics Inc. | Health Care | 1 | <0.01% | +$872K | 1 / 0 | 0 / 0 |
| RCEL | Avita Medical Inc. | Health Care | 1 | <0.01% | −$267K | 0 / 1 | 0 / 0 |
| COYA | Coya Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| SNN | Smith & Nephew PLC | Health Care | 1 | <0.01% | +$7M | 1 / 0 | 0 / 0 |
| FHTX | Foghorn Therapeutics Inc. | Health Care | 1 | <0.01% | −$20K | 0 / 0 | 0 / 0 |
| CMPX | Compass Therapeutics Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$1M | 1 / 0 | 1 / 0 |
| MLTX | Moonlake Immunotherapeutics IPO or spin-off | Health Care | 1 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| ALEC | Alector Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| PSNL | Personalis Inc. | Health Care | 1 | <0.01% | −$527K | 0 / 0 | 0 / 0 |
| GPCR | Structure Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| BDTX | Black Diamond Therapeutics I | Health Care | 1 | <0.01% | +$821K | 1 / 0 | 0 / 0 |
| AVBP | Arrivent Biopharma Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$9M | 1 / 0 | 1 / 0 |
| IART | Integra Lifesciences Hldgs | Health Care | 1 | <0.01% | +$454K | 1 / 0 | 0 / 0 |
| RCKT | Rocket Pharmaceuticals Inc. | Health Care | 1 −1 | <0.01% | +$7M | 1 / 1 | 0 / 1 |
| HALO | Halozyme Therapeutics | Health Care | 1 | <0.01% | −$798K | 0 / 1 | 0 / 0 |
| ARGX | Argenx Se | Health Care | 1 | <0.01% | −$18M | 0 / 1 | 0 / 0 |
| PVLA | Palvella Therapeutics Inc. | Health Care | 1 −1 | <0.01% | −$4M | 0 / 1 | 0 / 1 |
| AUTL | Autolus Therapeutics PLC | Health Care | 1 | <0.01% | −$367K | 0 / 1 | 0 / 0 |
| IPSC | Century Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CNTA | Centessa Pharmaceuticals PLC | Health Care | 1 −1 | <0.01% | −$4M | 0 / 1 | 0 / 1 |
| Catalyst Pharmaceutic… | Catalyst Pharmaceuticals Inc. | Health Care | 1 | <0.01% | +$12M | 1 / 0 | 0 / 0 |
| PYXS | Pyxis Oncology Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| IRD | Opus Genetics Inc. | Health Care | 1 | <0.01% | +$42K | 0 / 0 | 0 / 0 |
| DMAC | Diamedica Therapeutics Inc. | Health Care | 1 | <0.01% | +$98K | 0 / 0 | 0 / 0 |
| NGNE | Neurogene Inc. | Health Care | 1 | <0.01% | −$6K | 0 / 0 | 0 / 0 |
| TNGX | Tango Therapeutics Inc. | Health Care | 1 | <0.01% | +$23M | 1 / 0 | 0 / 0 |
| CERS | Cerus Corp. | Health Care | 1 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| ABSI | Absci Corp. | Health Care | 1 | <0.01% | −$2M | 0 / 1 | 0 / 0 |
| PHVS | Pharvaris N V | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ALDX | Aldeyra Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ARCT | Arcturus Therapeutics Holdings | Health Care | 1 | <0.01% | −$4M | 0 / 1 | 0 / 0 |
| ZLAB | Zai Lab Ltd | Health Care | 1 | <0.01% | −$8M | 0 / 1 | 0 / 0 |
| TFX | Teleflex Incorporated IPO or spin-off | Health Care | 1 +1 | <0.01% | +$42M | 1 / 0 | 1 / 0 |
| DERM | Journey Medical Corp. | Health Care | 1 | <0.01% | +$184K | 1 / 0 | 0 / 0 |
| ABEO | Abeona Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| NRIX | Nurix Therapeutics Inc. | Health Care | 1 −1 | <0.01% | −$1M | 0 / 1 | 0 / 1 |
| AQST | Aquestive Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ERAS | Erasca Inc. | Health Care | 1 | <0.01% | +$13K | 0 / 0 | 0 / 0 |
| USNA | Usana Health Sciences Inc. | Health Care | 1 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| IVVD | Invivyd Inc. | Health Care | 1 −1 | <0.01% | −$930K | 0 / 2 | 0 / 1 |
| GUTS | Fractyl Health Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| OSUR | Orasure Technologies Inc. | Health Care | 1 | <0.01% | −$24K | 0 / 1 | 0 / 0 |
| ADCT | Adc Therapeutics SA | Health Care | 1 | <0.01% | −$273K | 0 / 1 | 0 / 0 |
| NEOG | Neogen Corp. | Health Care | 1 −1 | <0.01% | −$5M | 0 / 2 | 0 / 1 |
| INBX | Inhibrx Biosciences Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TECX | Tectonic Therapeutic Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| NKTR | Nektar Therapeutics IPO or spin-off | Health Care | 1 +1 | <0.01% | +$258K | 1 / 0 | 1 / 0 |
| APRE | Aprea Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| IBIO | Ibio Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| RFL | Rafael Holdings Inc. Class B | Health Care | 1 | <0.01% | −$2K | 0 / 0 | 0 / 0 |
| GMED | Globus Med Inc. | Health Care | 1 | <0.01% | +$7M | 1 / 0 | 0 / 0 |
| RMD | Resmed | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| NUVL | Nuvalent Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| PRCT | Procept Biorobotics Corp. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$173K | 1 / 0 | 1 / 0 |
| TYRA | Tyra Biosciences Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| GANX | Gain Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
How the numbers work
Same managers in both quarters
Changes compare only managers with a 13F in both 2025 Q1 and 2025 Q2: 136 this time.
Buying versus price
Each holding’s dollar change splits into price (what last quarter’s shares earned by this quarter’s 13F price) and net bought (shares added or cut, times this quarter’s price), using each 13F’s own values. The two add back to the change exactly. Stock splits are adjusted first.
Who counts as a buyer or a seller
A manager bought a stock if it opened a position, or added at least 5% to its shares or a trade worth 0.25% of its book; it sold if it closed the position or cut it by the same amounts. Smaller changes count as holding, and a stock split never counts. A manager was a net buyer for the quarter when its trading added up to at least 0.25% of its book. GOOG and GOOGL count once.
IPOs, spin-offs and mergers
A stock no tracked manager held last quarter (an IPO, a spin-off, a new share class) is not counted as buying, and one nobody holds now (a merger, a delisting) is not counted as selling. Choose them under All names to see them.
Each manager once, or by dollars
By default every manager counts the same, so a list leads with what the most managers did. By dollars ranks by money moved and weighs holdings by size, so the largest books set the order.
Sectors
GICS sectors where the company has one. Funds, foreign listings and private shares have none; their buying is shown on its own, never filed under Other. Sector weights are shares of the names that have a sector.
The combined book against SPY
Each quarter-end’s combined book is held to the next quarter-end at the 13Fs’ own prices: price only, no dividends, and today’s featured managers for every quarter. SPY is the same filings’ price for SPY. It is a record of what the managers held, not something anyone could have copied, because 13Fs arrive about 45 days after the quarter ends.
What a 13F leaves out
Long US-listed stock only: no shorts, cash, bonds or foreign listings, and options are left out here.